

FIG. 1

		P22				Y91					L265
	HDLP	P	L	G	G	Y	E	N	P	Y	L
Class I	HDAC1	P	M	G	-	E	D	C	P	R	L
	HDAC2	P	M	G	-	E	D	C	P	R	L
	HDAC3	P	M	G	-	D	D	C	P	R	L
	HDAC8	A	K	G	-	Y	D	С	P	P	M
ſ	HDAC4	P	E	G	V	D	S	D	T	P	L
	HDAC5	P	E	G	V	D	S	D	T	P	L
Class II	HDAC6(a)	P	E	-	-	-	-	D	S	P	K
	HDAC6(b)	P	E	-	-	-	-	D	S	P	L
	HDAC7	P	E	G	G	D	T	D	T	P	L

Compound	HDAC1	HDAC6
8	1.2 ± 0.5	0.9 ± 0.2
9 10	1.7 ± 1.2 1.5 ± 0.2	1.1 ± 0.1 0.38 ± 0.04



FIG








FIG. 9A

FIG. 9B

FIG. 9C

FIG. 10






FIG. 11





Notes: TSA treatment at 300nM JCWII114 treatment at 2 µM

FIG. 13A




FIG. 13B





FIG. 13C



Acetylated Tubulin OSMO CWII153

Acetylated Histone H3





FIG. 15

DMSO	TSA (200 nM)
JCWII114 (2 μM)	JCWII153 (2 μM)
JCWII169 (2 μM)	JCWII169 (20 μM)

FIG. 16

DMSO	TSA (200 nM)
JCWII114 (2 μM)	JCWII153 (2 μM)
JCWII169 (2 μM)	JCWII169 (20 μM)

FIG. 17A



0.2 µM TSA JCWII153 2.0 µM 2.0 µM 2.0 µM 2.0 µM 2.0 µM

FIG. 17B





FIG. 17C

FIG. 20A

FIG. 20D

FIG. 21A



To FIG. 21B

FIG. 21B

FIG. 21C

а	cetal	3-ероху	acetal	3-ероху
frag	ment	alcohols	fragment	alcohols
	103	104 200 250	117	404400 470
	5 1	194 208 270	m 4	194 208 270
	71 70	368 382 444	71	382 396 458
	78	375 389 451	78	389 403 465
	87	384 398 460	87	398 412 474
	101	398 412 474	101	412 426 488
	101	398 412 474	101	412 426 488
	111	408 422 484	111	422 436 498
	113	410 424 486	113	424 438 500
	116	413 427 489	116	427 441 503
	118	415 429 491	118	429 443 505
	125	422 436 498	125	436 450 512
Ś	126	423 437 499	126	437 451 513
hile	127	424 438 500	127	438 452 514
nucleophiles	132	429 443 505	132	443 457 519
말	136	433 447 509	136	447 461 523
ח	136	433 447 509	136	447 461 523
30	143	440 454 516	143	454 468 530
	154	451 465 527	154	465 479 541
	155	452 466 528	155	466 480 542
	164	461 475 537	164	475 489 551
	165	462 476 538	165	476 490 552
	167	464 478 540	167	478 492 554
	167	464 478 540	167	478 492 554
	193	490 504 566	193	504 518 580
	194	491 505 567	194	505 519 581
	211	508 522 584	211	522 536 598
	217	514 528 590	217	528 542 604
	221	518 532 594	221	532 546 608
	231	528 542 604	231	542 556 618
	253	550 564 626	253	564 578 640
	263	560 574 636	263	574 588 650
			То	

₩ FIG. 21D






FIG. 22/

FIG. 22B




FIG. 22C




FIG. 23A

FIG. 23B




FIG. 24A




FIG. 24B




FIG. 24C

	Uretupamine	Rº	R ¹	R ²	R²	Activity
$ \begin{array}{c} R^3 \\ \bigcirc \bigcirc \bigcirc \bigcirc \\ R^0 \\ R^1 \end{array} $ S_{R^2}	ABCDEFGH	HOCH ₂ -4-Ph HOCH ₂ -4-Ph HOCH ₂ -4-Ph HOCH ₂ -4-Ph HOCH ₂ -4-Ph HOCH ₂ -4-Ph HOCH ₂ -4-Ph	Ph H (β)-CH ₃ H H H H	2-MDPO 2-MDPO 2-MDPO Ph 2-MBO 2-MDPO 2-MDPO 2-MDPO	CH ₂ NH ₂ CH ₂ NH ₂ CH ₂ NH ₂ CH ₂ NH ₂ CH ₂ NH ₂ H CH ₂ NHAC CH ₂ NH ₂	56 105 41* 7 10 14 16

FIG. 24D





FIG. 25A

Wild type

Ure2 ∆



	w.t.	Ure2 ∆
PUT1	+4.0	+1.1
PUT2	+2.3	+1.1
UGA1	+2.2	+1.2
NIL1	+3.8	+1.1
PRB1	+4.0	+1.7

FIG. 25B

Gene sets	w.t.	gln3⊿	nil1⊿	ure2⊿
GAP1, MEP2, DAL5, BAT2, AGP1	+1.1	+1.1	-1.0	-1.0
PUT1, PUT2, UGA1, NIL1, PRB1	+2.3	+2.5	+1.6	+1.2

FIG. 25C

Gene sets	w.t.	gln3⊿	nil1∆	ure2∆
Whole genome	100%	89%	56%	52%
URE2-dependent genes	100%	115%	51%	59%

31/78

FIG. 26A

Control Rapamycin Proline Acetate Glycerol

Ure2p

FIG. 26B

Nodrug Rapamycin Sorbitol NaCl pH 9.5

Ure2p

FIG. 26C


Whole genome Storage carbohydrates Hexose transporters DNA replication Purine biosynthesis Proteasome Ure2p-dependent Glycolysis TCA cycle Oxidative phosphorylation Ubiquinone synthesis ATP synthesis RNA Pd I RNA Pd II RNA Pd III tRNA processing tRNA synthesases mito tRNA synthesases r-proteins mito r-proteins Ribosomal biogenesis rRNA processing Translation initiation Translation elongation mRNA export mRNA decay

Correlated Uncorrelated Anticorrelated


FIG. 26D

	Ethanol	Acetate
PUT1	+11.5	> +10.0
PUT2	+2.8	+1.6
UGA1	+4.7	+3.3
NIL1	+2.6	+2.5
PRB1	+2.3	+1.4
GAP1	+3.3	-9.0
DAL1	+1.7	-4.8
DAL2	+3.1	-1.5
DAL3	+2.1	< -10.0
CAR1	+2.6	-1.4

FIG. 26E








- 8₁ = [20]

1,3-dioxane core skeleton



Biasing elements in diversity-oriented synthesis

FIG. 27C

Compounds screened in duplicate	7,392 2,464 hydroxamic acids	7,392 2,464 hydroxamic acids 2,464 hydroxamic acids
Abbreviation	AcTubulin ITSA1+AcTubulin	AcLysine AcHistH3 AcHistH4
Assay	Acetylated tubulin Acetylated tubulin + ITSA1 (chemical genetic modifier)	Acetylated lysine Acetylated histone H3 Acetylated histone H4
	1 . 2.	ა. 4. ი .

Table 1. Summary of chemical genetic screens

FIG. 28A




FIG. 28B




FIG. 28C




FIG. 28D





FIG. 29A



Std. relative tubulin acetylation

FIG. 29B






FIG. 29C



Top 200 ranked compounds

FIG. 29D



Top 10 selective AcTubulin







FIG. 30B



Relative index value

- = (A) AcTubulin assay node
- = (B) AcLysine assay node
- = (C) ITSA1+ AcTubulin assay node

FIG. 30C





FIG. 31








FIG. 33B




FIG. 33C




FIG. 34A

FIG. 36A

FIG. 36B




FIG. 36C

FIG. 36D





FIG. 36E






FIG. 37D




FIG. 38




FIG. 39






FIG. 40








FIG. 41E




FIG. 41F





FIG. 42A

	DMSO	TSA	tubacin
DMSO	1.1	0.2	0.99
TSA	0.2	1.**	0.23
tubacin	0.99	0.23	1 //

Pearson correlation coefficients (r)



increased decreased
Neares t-neighbor clustering

FIG. 42B





FIG. 42C



FIG. 42D



ZF-UBP HDAC6 domain organization & properties PILOH WOLCH HDAC/TDAC domain 2 domain 1 TOUTH TO WALL HDAC biloh policy YOO GAN, X by long 180 POIL X POICH, **FIG. 43C** YOU DE CHY YOUNGH! DOLL tools! A Thubach in Market o-tubul in (a-1.ys 40) Ac Tubul in (a. Ly s 40) ա- ւսեռի քա

62/78

FIG. 43B

FIG. 43A

FIG. 43D




FIG. 43E



FIG. 43F






FIG. 44A



DMSO pre-treatment



tubacin (2 μM) pre-treatment

FIG. 44B




FIG. 44C





FIG. 44D







FIG. 451



Biasing elements in diversity-oriented synthesis

FIG. 46





FIG. 47A

Treatment	Mean x-tubulin acetylation
DMSO	92
ITSA1	82
TSA	322
TSA + ITSA1	104
tubacin	183
tubacin + ITSA1	110

FIG. 47B






FIG. 47G





FIG. 47H



interphase prophase metaphase telophase

FIG. 48A




FIG. 48B






FIG. 49C

FIG. 49B

DMSO

tubacin (10 μM)





IG. 50B

FIG. 50C




FIG. 50D

